Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.45 |
| ▸ | GRM5 | P41594 | 9/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16804402 | 0.94 | WNT3A (0.46) | WNT3AGRM1GRM5HDAC1HDAC6 | |
| SCHEMBL16804278 | 0.91 | HDAC6 (0.46) | WNT3AGRM1GRM5HDAC1HDAC6 | |
| SCHEMBL18109040 | 0.85 | GRM1 (0.45) | WNT3AGRM1GRM5HDAC1HDAC6 | |
| SCHEMBL16804188 | 0.85 | HDAC6 (0.46) | WNT3AGRM1GRM5HDAC1HDAC6 | |
| SCHEMBL16804344 | 0.84 | GRM1 (0.45) | WNT3AGRM1GRM5HDAC1HDAC6 | |
| SCHEMBL16804334 | 0.84 | CYP11B2 (0.43) | WNT3AGRM1GRM5HDAC1HDAC6 | |
| SCHEMBL18108924 | 0.84 | KIT (0.43) | WNT3AGRM1GRM5HDAC1HDAC6 | |
| SCHEMBL16804305 | 0.82 | TNK2 (0.44) | WNT3AGRM1GRM5HDAC1HDAC6 | |
| SCHEMBL18109101 | 0.81 | GRM1 (0.44) | WNT3AGRM1GRM5HDAC1HDAC6 | |
| SCHEMBL15961880 | 0.79 | GRM1 (0.53) | WNT3AGRM1GRM5JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080125-B1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2018-10-10 | — | — | EP | disclosed |
| US-9650379-B2 | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-16 | — | — | US | disclosed |
| US-9650379-B2 | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-16 | — | — | US | disclosed |
| US-9650379-B2 | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-16 | — | — | US | disclosed |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-10-06 | — | — | US | disclosed |
| WO-2015087151-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HDAC5, HDAC1, HDAC2 | WNT3A 1628/4885GRM1 2621/4885GRM5 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.